An option for patients with Parkinson’s and LRRK2 mutation
Related Stories



21 de November de 2023
We evaluated an inhibitor of the LRRK 2 gene in patients with Parkinson’s. Oral treatment….
Posted in: Uncategorized

8 de May de 2023
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
Posted in: Parkinson

8 de May de 2023
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
Posted in: Parkinson

16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…

8 de June de 2021
The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC), has included the…
Posted in: News

8 de June de 2021
The Hospital Universitari General de Catalunya, which was the first center in Spain activated for…
Posted in: News